GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Grainne M O'KaneSandra E Fischer

Abstract

To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate biomarker. Within the COMPASS trial, patients proceeding to chemotherapy for advanced PDAC undergo tumor biopsy for RNA-sequencing (RNA-seq). Overall response rate (ORR) and overall survival (OS) were stratified by subtypes and according to chemotherapy received. Correlation of GATA6 with the subtypes using gene expression profiling, in situ hybridization (ISH) was explored. Between December 2015 and May 2019, 195 patients (95%) had enough tissue for RNA-seq; 39 (20%) were classified as basal-like and 156 (80%) as classical. RECIST response data were available for 157 patients; 29 basal-like and 128 classical where the ORR was 10% versus 33%, respectively (P = 0.02). In patients with basal-like tumors treated with modified FOLFIRINOX (n = 22), the progression rate was 60% compared with 15% in classical PDAC (P = 0.0002). Median OS in the intention-to-treat population (n = 195) was 9.3 months for classical versus 5.9 months for basal-like PDAC (HR, 0.47; 95% confidence interval, 0.32-0.69; P = 0.0001). GATA6 expression by RNA-seq highly correlated with the classifier (P <...Continue Reading

References

May 14, 2004·The Journal of Pathology·Dalia M Abd El-RehimIan O Ellis
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Jun 26, 2012·Journal of Surgical Oncology·Jordan M WinterJonathan R Brody
Oct 30, 2012·Bioinformatics·Alexander DobinThomas R Gingeras
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Apr 11, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Y DouillardR Sidhu
May 15, 2015·Nature·Stefani SprangerThomas F Gajewski
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 26, 2016·Nature·Peter BaileySean M Grimmond
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Aug 16, 2017·Cancer Cell·UNKNOWN Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, UNKNOWN Cancer Genome Atlas Research Network
Dec 6, 2017·Scientific Reports·Peter BankheadPeter W Hamilton
Dec 31, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kyaw L AungJennifer J Knox
Jun 2, 2018·Cancer Discovery·Hervé TiriacDavid A Tuveson
Dec 24, 2018·The New England Journal of Medicine·Thierry ConroyUNKNOWN Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group
Feb 6, 2019·Nature Reviews. Gastroenterology & Hepatology·Eric A CollissonAndrew V Biankin
Jun 4, 2019·The New England Journal of Medicine·Talia GolanHedy L Kindler
Aug 4, 2019·Scientific Reports·Lucia Roa-PeñaLuisa F Escobar-Hoyos
Oct 20, 2019·Nature Communications·Xianlu Laura PengJen Jen Yeh
Jul 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Y DouillardR Sidhu

❮ Previous
Next ❯

Citations

Apr 23, 2020·International Journal of Molecular Sciences·Luca PompellaFerdinando De Vita
Jul 15, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric A Collisson
Jan 8, 2021·Journal of Clinical Medicine·Fieke E M FroelingDavid K Chang
Nov 15, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R NicolleN J Dusetti
Oct 24, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·ChongFeng GaoBrian B Haab
Feb 19, 2021·Molecular and Cellular Biochemistry·Mastan MannarapuObul Reddy Bandapalli
Mar 7, 2021·International Journal of Molecular Sciences·Yolanda Rodríguez GilVíctor Javier Sánchez-Arévalo Lobo
Feb 19, 2021·Computational and Structural Biotechnology Journal·M P HumphriesM Salto-Tellez
Feb 28, 2021·Seminars in Oncology·Binbin Zheng-Lin, Eileen M O'Reilly
Mar 5, 2021·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Mª A Gómez-EspañaJ Feliu
Mar 21, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Marc HilmiRemy Nicolle
Nov 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R CasolinoT Golan
May 11, 2021·Frontiers in Genetics·Deborah WeighillJohn Quackenbush
Jun 6, 2021·Nature Reviews. Gastroenterology & Hepatology·Akimasa HayashiChristine A Iacobuzio-Donahue
Jul 3, 2021·International Journal of Molecular Sciences·Jorge Melendez-Zajgla, Vilma Maldonado
Jul 16, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Henry C-H LawNicholas T Woods
Aug 3, 2021·Frontiers in Oncology·Penelope EdwardsIan Chau
Oct 15, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James T TophamDavid F Schaeffer
Aug 18, 2021·Der Pathologe·Anna Melissa SchlitterGünter Klöppel
Aug 25, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harshabad SinghAndrew J Aguirre
Oct 14, 2021·Cell·Barbara T GrünwaldRama Khokha
Sep 8, 2021·Cancer Metastasis Reviews·Rayane DennaouiKay-Uwe Wagner
Nov 4, 2021·Expert Opinion on Investigational Drugs·Byung Woog Kang, Ian Chau
Nov 16, 2021·JAMA Network Open·Nguyen H Tran, Tanios Bekaii-Saab

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.